In September 2025, the FDA issued a series of warning letters to online sellers of compounded GLP-1 medications, and in February 2026, Novo Nordisk filed suit against Hims & Hers, alleging patent infringement through compounded semaglutide products
Research-community sources cluster between 20 and 100 mcg per day, given as one daily SubQ or IM injection
PlexusDx's Precision Peptide Genetic Test ($298) identifies genetic variants like GLP1R rs6923761 that determine how your cells respond to semaglutide
The launch is also expected to spur consumer-focused offerings to support patients on therapy
A pre-treatment lipid panel documents your cardiovascular risk baseline and enables your provider to measure this improvement over time
Full testing documentation is included on every product, so researchers have the analytical data to support their experimental protocols